NDAORALCAPSULEPriority Review
Approved
Jun 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
MINIPRESS (prazosin hydrochloride) by Pfizer is clinical pharmacology the exact mechanism of the hypotensive action of prazosin is unknown. First approved in 1976.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINIPRESS (prazosin hydrochloride) is an oral alpha-adrenergic blocker approved in 1976 for hypertension management. It lowers blood pressure by blocking postsynaptic alpha-adrenoceptors on vascular smooth muscle, reducing total peripheral resistance without causing reflex tachycardia. The drug is notable for maintaining stable hemodynamics with no adverse lipid profile changes.
$0.014BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal current spending; brand team likely focused on defending legacy market share against generics and newer agents.
Mechanism of Action
CLINICAL PHARMACOLOGY The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the…
Indications
Worked on MINIPRESS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.